Orthofix Medical Inc. OFIX

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived Nasdaq

Orthofix is a global medical technology company headquartered in Lewisville, Texas. By providing medical technologies that heal musculoskeletal pathologies, Orthofix delivers exceptional experiences and life-changing solutions to patients around the world. Orthofix offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System.

The Company was founded in Verona, Italy in 1980 and formally incorporated in 1987 in Curaçao as "Orthofix International N.V." In 2018, we completed a change in our jurisdiction of organization from Curaçao to the State of Delaware and changed our name to "Orthofix Medical Inc." As a result, we are a corporation existing under the laws of the State of Delaware.

Last close 9.81 2026-10-23
Market cap $399.6M 2026-06-30 share count
52-week range 8.50 - 16.99

Valuation FY2025 figures against the last close

P/S0.5x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-2.33

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • U.S.
  • Others
  • Italy
  • United Kingdom
  • France
  • Germany
  • Other
Revenue by geography, 7 categories over 3 years. The same figures are in the table below. FY2025 U.S., FY2025: 684.1M (83.2%) 83% U.S. Others, FY2025: 76.7M (9.3%) 9% Others Italy, FY2025: 22.3M (2.7%) United Kingdom, FY2025: 13.3M (1.6%) France, FY2025: 12M (1.5%) Germany, FY2025: 9.1M (1.1%) Other, FY2025: 4.8M (0.6%) FY2024 U.S., FY2024: 672.8M (84.2%) 84% Others, FY2024: 66.4M (8.3%) 8% Italy, FY2024: 21M (2.6%) United Kingdom, FY2024: 11.2M (1.4%) France, FY2024: 13.4M (1.7%) Germany, FY2024: 9M (1.1%) Other, FY2024: 5.7M (0.7%) FY2023 U.S., FY2023: 620.8M (83.1%) 83% Others, FY2023: 65.8M (8.8%) 9% Italy, FY2023: 20.1M (2.7%) United Kingdom, FY2023: 10.9M (1.5%) France, FY2023: 11.1M (1.5%) Germany, FY2023: 11.5M (1.5%) Other, FY2023: 6.5M (0.9%)
Region FY2025FY2024FY2023
U.S. $684.1M $672.8M $620.8M
Others $76.7M $66.4M $65.8M
Italy $22.3M $21.0M $20.1M
United Kingdom $13.3M $11.2M $10.9M
France $12.0M $13.4M $11.1M
Germany $9.1M $9.0M $11.5M
Other $4.8M $5.7M $6.5M

As the company reported it, from the “Business Segment Information - Summary of Net Sales by Geographic Destination (Detail)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Revenue by segment

  • Global Spine
  • Global Limb Reconstruction
Revenue by segment, 2 categories over 3 years. The same figures are in the table below. FY2025 Global Spine, FY2025: 687.7M (83.6%) 84% Global Spine Global Limb Reconstruction, FY2025: 134.7M (16.4%) 16% FY2024 Global Spine, FY2024: 675.3M (84.5%) 84% Global Limb Reconstruction, FY2024: 124.2M (15.5%) 16% FY2023 Global Spine, FY2023: 631.3M (84.6%) 85% Global Limb Reconstruction, FY2023: 115.3M (15.4%) 15%
Segment FY2025FY2024FY2023
Global Spine $687.7M $675.3M $631.3M
Global Limb Reconstruction $134.7M $124.2M $115.3M

As the company reported it, from the “Business Segment Information - Summary of Net Sales by Geographic Destination for Each Reporting Segment (Detail)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $822.3M$799.5M$746.6M$460.7M$464.5M$406.6M$460.0M$453.0M$433.8M$409.8M
Cost of revenue $256.3M$253.6M$260.4M$123.5M$114.9M$101.9M$100.6M$96.6M$93.0M$87.9M
Gross profit $566.0M$545.9M$486.3M$337.2M$349.6M$304.7M$359.3M$356.4M$340.8M$321.9M
R&D $65.8M$73.6M$80.2M$49.1M$49.6M$39.1M$34.6M$33.2M$29.7M$28.8M
SG&A $554.3M$532.5M$530.4M$308.8M$69.4M$67.9M$85.6M$83.3M$71.9M$76.4M
Total operating expenses ——————$378.1M$326.3M$300.0M$300.9M
Operating income -$81.4M-$84.6M-$139.1M-$13.3M-$8.3M-$6.3M-$18.8M$30.1M$40.8M$21.1M
Interest expense $17.5M$29.6M$8.6M$1.3M$1.8M$2.5M$122.0K$828.0K$416.0K$763.0K
Pre-tax income -$90.8M-$123.9M-$148.7M-$17.7M-$13.5M-$368.0K-$27.0M$22.9M$36.4M$19.0M
Income tax $1.4M$2.1M$2.7M$2.0M$24.9M$2.9M$1.4M$9.1M$29.1M$15.5M
Net income -$92.2M-$126.0M-$151.4M-$19.8M-$38.4M$2.5M-$28.5M$13.8M$6.2M$3.1M
EPS, basic -2.33-3.30-4.12-0.98-1.950.13-1.510.730.340.17
EPS, diluted -2.33-3.30-4.12-0.98-1.950.13-1.510.720.340.17
Shares, diluted (wtd. avg.) 39.6M38.1M36.7M20.1M19.7M19.4M18.9M18.9M18.5M18.5M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $82.0M$83.2M$33.1M$50.7M$87.8M$96.3M$69.7M$69.6M$81.2M$39.6M
Receivables $135.7M$134.7M$128.1M$82.9M$78.6M$72.4M$86.8M$77.7M$63.4M$57.8M
Inventory $172.3M$189.5M$222.2M$100.2M$83.0M$84.6M$82.4M$76.8M$81.3M$63.3M
Total current assets $416.8M$433.3M$420.4M$256.0M$269.5M$270.4M$260.6M$244.6M$251.8M$194.4M
Property, plant and equipment $129.4M$139.8M$159.1M$58.2M$59.3M$63.6M$62.7M$42.8M$45.1M$48.9M
Goodwill $194.9M$194.9M$194.9M$71.3M$71.3M$84.0M$71.2M$72.4M$53.6M$53.6M
Other intangibles $72.8M$98.8M$117.5M$47.4M$52.7M$60.5M$54.1M$51.9M$10.5M$7.5M
Total assets $850.6M$893.3M$925.3M$458.6M$476.6M$525.9M$495.6M$466.6M$405.4M$372.1M
Accounts payable $58.4M$48.8M$58.4M$27.6M$26.5M$23.1M$19.9M$18.0M——
Short-term debt $0$0$1.2M———————
Total current liabilities $170.5M$168.6M$165.2M$83.6M$105.8M$103.9M$84.9M$85.9M$79.4M$83.4M
Long-term debt $157.4M$157.0M$93.1M———————
Total liabilities $400.6M$390.2M$326.6M$121.8M$139.7M$169.0M$168.0M$131.2M$108.7M$108.6M
Retained earnings -$368.3M-$276.1M-$150.1M$1.3M$21.0M$59.4M$57.7M$87.1M$70.4M$64.2M
Total equity $450.0M$503.1M$598.7M$336.9M$336.9M$356.9M$327.6M$335.4M$296.6M$263.5M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $33.3M$25.8M-$45.8M-$11.5M$18.5M$74.3M$32.0M$49.9M$39.0M$59.1M
Depreciation and amortisation $77.3M$60.1M$53.1M$29.0M$29.6M$30.5M$24.7M$18.7M$20.1M$20.8M
Stock-based compensation $28.7M$32.5M$35.7M$18.4M$15.4M$16.2M$21.5M$18.9M$12.6M$16.0M
Capital expenditure $34.6M$34.9M$62.0M$23.2M$17.8M$15.5M$19.0M$13.6M$14.7M$16.4M
Investing cash flow -$34.6M-$27.6M-$33.1M-$24.5M-$23.0M-$52.3M-$22.9M-$61.0M-$16.5M-$21.9M
Financing cash flow -$786.0K$50.7M$65.3M-$78.0K-$3.6M$3.2M-$10.7M$3.0M$3.5M-$46.1M
Buybacks —————————$63.4M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-191716.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -250M 0 250M 500M 750M 1B Revenue, FY2016: 409.8M Gross profit, FY2016: 321.9M Net income, FY2016: 3.1M Revenue, FY2017: 433.8M Gross profit, FY2017: 340.8M Net income, FY2017: 6.2M Revenue, FY2018: 453M Gross profit, FY2018: 356.4M Net income, FY2018: 13.8M Revenue, FY2019: 460M Gross profit, FY2019: 359.3M Net income, FY2019: -28.5M Revenue, FY2020: 406.6M Gross profit, FY2020: 304.7M Net income, FY2020: 2.5M Revenue, FY2021: 464.5M Gross profit, FY2021: 349.6M Net income, FY2021: -38.4M Revenue, FY2022: 460.7M Gross profit, FY2022: 337.2M Net income, FY2022: -19.8M Revenue, FY2023: 746.6M Gross profit, FY2023: 486.3M Net income, FY2023: -151.4M Revenue, FY2024: 799.5M Gross profit, FY2024: 545.9M Net income, FY2024: -126M Revenue, FY2025: 822.3M Gross profit, FY2025: 566M Net income, FY2025: -92.2M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $409.8M $433.8M $453.0M $460.0M $406.6M $464.5M $460.7M $746.6M $799.5M $822.3M
Gross profit $321.9M $340.8M $356.4M $359.3M $304.7M $349.6M $337.2M $486.3M $545.9M $566.0M
Net income $3.1M $6.2M $13.8M -$28.5M $2.5M -$38.4M -$19.8M -$151.4M -$126.0M -$92.2M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Regulation FD disclosure Item 7.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%